MetaCap

Fennec Pharmaceuticals (FENC) vs Tevogen (TVGN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Fennec Pharmaceuticals (FENC) has outperformed Tevogen (TVGN) over the past year, gaining 66.1% versus a loss of 73.8%. Fennec Pharmaceuticals is the larger company by market cap ($462.1 million vs $405.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FENC+66.12%TVGN-73.84%
+80%-5%-91%
Nov 21, 20251 yearNov 20, 2026
FENC+189.60%TVGN-98.81%
+204%+45%-114%
Jan 3, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FENC versus TVGN key metrics
MetricFENCTVGN
Share price$13.09$5.90
Market cap$462.14M$405.20M
1-day change-2.68%-6.35%
YTD return+70.00%-64.35%
1-year return+66.12%-73.84%
5-year return+35.79%—
P/E ratio (TTM)436.33—
Forward P/E12.47—
EPS (TTM)$0.03$-7.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$44.64M—
Revenue growth (YoY)-6.09%—
Net income (latest FY)$-9.74M$-26.28M
Operating margin-14.07%—
Net margin-21.82%—
52-week high$13.85$24.90
52-week low$5.65$3.64
Distance from 52-week high-5.49%-76.31%
Analyst consensusstrong_buy—
Avg. price target upside+34.45%—
Average volume220.87K7.94K
Shares outstanding35.31M68.68M
Employees3518
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • FENC has outperformed TVGN by 140.0 percentage points over the past year.

About Fennec Pharmaceuticals

FENC stock →

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees

About Tevogen

TVGN stock →

Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees

FENC vs TVGN FAQ

Which is bigger, Fennec Pharmaceuticals or Tevogen?

Fennec Pharmaceuticals (FENC) is larger, with a market capitalization of $462.14M compared with $405.20M for Tevogen (TVGN).

Which stock has performed better over the past year, FENC or TVGN?

FENC returned +66.12% over the past 12 months, compared with -73.84% for TVGN (price return, excluding dividends). Past performance does not predict future results.

Are Fennec Pharmaceuticals and Tevogen in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons